Shown to be highly effective in strengthening bones and protecting against fractures in all key sites, including hip and spine[1] Once-yearly dosing provides potential for compliance benefits and long ...
01 February 2009Single-dose therapy given once a year shown to provide significant bone protection benefits and may improve long-term treatment compliance Amman - Jordan - Aclasta (zoledronic acid 5 ...
ZURICH (MarketWatch) -- Drugmaker Novartis AG NVS said Friday that the European Union regulator had approved its bone drug Aclasta, a treatment which needs to be taken only once a year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback